HRR mutational status is prognostic and predictive biomarker olaparib activity Presented ByDr Joyce Liu, Dana-Farber Cancer Institute, MA, USA TrialPhase 3, NRG-GY004 ConferenceESMO 2021 19 November, 2021 09:20
